Alto Ingredients (ALTO) Panoramica del titolo
Alto Ingredients, Inc. produce, distribuisce e commercializza alcoli speciali, carburanti rinnovabili e ingredienti essenziali negli Stati Uniti. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 5/6 |
| Crescita futura | 3/6 |
| Prestazioni passate | 3/6 |
| Salute finanziaria | 5/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
ALTO ha superato i nostri controlli di rischio.
ALTO Community Fair Values
Create NarrativeSee what 22 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Alto Ingredients, Inc.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$5.65 |
| Massimo di 52 settimane | US$6.00 |
| Minimo di 52 settimane | US$0.92 |
| Beta | 0.14 |
| Variazione di 1 mese | 22.29% |
| Variazione a 3 mesi | 21.24% |
| Variazione di 1 anno | 413.64% |
| Variazione a 3 anni | 124.21% |
| Variazione a 5 anni | -5.68% |
| Variazione dall'IPO | -99.44% |
Notizie e aggiornamenti recenti
Aggiornamento della narrazione • Jun 04
ALTO: Funded MASH Path And Liver Programs Are Expected To Drive Upside
Analysts have lifted the fair value estimate for Alto Ingredients to $9.00 from $6.75, reflecting updated assumptions around revenue growth, margins, and a lower projected P/E multiple informed by recent Street research on comparable clinical and funding setups. Analyst Commentary Recent Street research on peer companies in adjacent clinical and funding situations highlights how valuation work is being reshaped by dilution, funding visibility, and evolving program focus.
Aggiornamento della narrazione • May 15
ALTO: Future Returns Will Hinge On MASH Trials And Alcohol Liver Data
Alto Ingredients' analyst price target has been revised higher to $8.00 from $4.50, with analysts citing updated assumptions about the discount rate, revenue growth, profit margin, and future P/E to reflect recent research on the company's pipeline and market opportunities. Analyst Commentary While the revised US$8.00 price target reflects updated assumptions about Alto Ingredients' potential, some of the broader Street research on comparable stocks highlights why not all analysts are leaning in aggressively on valuation.Recent updates
Aggiornamento della narrazione • Jun 04
ALTO: Funded MASH Path And Liver Programs Are Expected To Drive Upside
Analysts have lifted the fair value estimate for Alto Ingredients to $9.00 from $6.75, reflecting updated assumptions around revenue growth, margins, and a lower projected P/E multiple informed by recent Street research on comparable clinical and funding setups. Analyst Commentary Recent Street research on peer companies in adjacent clinical and funding situations highlights how valuation work is being reshaped by dilution, funding visibility, and evolving program focus.Aggiornamento della narrazione • May 15
ALTO: Future Returns Will Hinge On MASH Trials And Alcohol Liver Data
Alto Ingredients' analyst price target has been revised higher to $8.00 from $4.50, with analysts citing updated assumptions about the discount rate, revenue growth, profit margin, and future P/E to reflect recent research on the company's pipeline and market opportunities. Analyst Commentary While the revised US$8.00 price target reflects updated assumptions about Alto Ingredients' potential, some of the broader Street research on comparable stocks highlights why not all analysts are leaning in aggressively on valuation.Aggiornamento della narrazione • Apr 23
ALTO: MASH And Alcohol-Related Liver Programs Will Drive Future Upside Potential
Alto Ingredients' analyst fair value estimate has shifted from $4.00 to $6.75 as analysts factor in updated assumptions on discount rate, revenue growth, margins, and a higher future P/E in light of recent bullish coverage and revised price targets tied to pemvidutide's MASH and alcohol-related disease programs. Analyst Commentary Bullish Takeaways Bullish analysts are focused on pemvidutide as a differentiated asset for MASH and alcohol-related liver disease.Aggiornamento della narrazione • Apr 09
ALTO: Future Returns Will Depend On MASH Trials And Alcohol Liver Data
Analysts have raised Alto Ingredients' price target to $25 from $12, citing pemvidutide's potential in MASH and alcohol-related liver and use disorders as key factors behind the revision. Analyst Commentary Recent Street research on Alto Ingredients highlights a mixed backdrop, with optimistic views on pemvidutide and the MASH program set against more cautious assessments of risk and valuation.Aggiornamento della narrazione • Mar 26
ALTO: Future Returns Will Hinge On MASH Trials And Funding Discipline
Analysts have raised their average price target for Alto Ingredients to $25 from $12, citing a sharpened focus on the planned MASH pivotal program and added potential value from pemvidutide in alcohol use disorder and alcohol liver disease, along with a solid cash runway and upcoming clinical catalysts. Analyst Commentary Recent Street research on Altimmune reflects a mix of optimism around the clinical pipeline and caution around execution risks and valuation.Aggiornamento della narrazione • Mar 11
ALTO: Future Returns Will Depend On Execution And Funding Discipline
Analysts have raised their price target on Alto Ingredients to $4.50 from $3.00, citing updated assumptions around fair value, discount rate, expected revenue growth, profit margins, and future P/E that they say are more in line with recent Street research on comparable companies. Analyst Commentary While the higher price target reflects updated valuation work, some bearish analysts in the broader small cap space are still emphasizing execution and funding risks that can weigh on sentiment for companies like Alto Ingredients.Aggiornamento della narrazione • Feb 25
ALTO: Future Upside Will Depend On Delivering Consistent Margin Execution
Analysts have adjusted their price target on Alto Ingredients to $3.00, with the neutral fair value and updated assumptions on discount rate, revenue growth, profit margin, and future P/E reflecting a refined view of the company’s risk and earnings profile following recent supportive research coverage. Analyst Commentary Recent research on Alto Ingredients has focused on reassessing the balance between potential upside and the risks tied to execution, earnings quality, and market conditions.Aggiornamento della narrazione • Feb 11
ALTO: Fair Outlook Will Rely On Sustaining Margins And Execution
Analysts have raised their price target for Alto Ingredients to US$3.00, reflecting updated views that include modestly higher revenue growth, slightly stronger profit margins, a lower discount rate, and a revised future P/E assumption, supported in part by recent bullish Street research. Analyst Commentary While the updated US$3.00 price target points to a more constructive stance overall, some bearish analysts remain cautious and continue to flag risk around how Alto Ingredients can justify this valuation through execution and earnings delivery.Aggiornamento della narrazione • Jan 27
ALTO: Upcoming Liver Meeting Data Will Support Repriced Risk Reward Profile
Analysts recently trimmed their 12 month price target on Alto Ingredients by US$1 to US$14, citing refreshed assumptions around discount rates, revenue growth, profit margins, and future P/E multiples. Analyst Commentary Bearish analysts trimming price targets on comparable small cap names to around US$14, even when maintaining constructive ratings, suggest a tighter margin for error around assumptions such as discount rates, revenue growth, profit margins, and future P/E multiples.Aggiornamento della narrazione • Jan 12
ALTO: Upcoming Late-Stage Liver Data Will Support Repriced Risk Reward Profile
Narrative Update: Alto Ingredients Analyst Price Target Shift Analysts have trimmed their price target on Alto Ingredients by $1 to $14, citing updated risk and growth assumptions after the timing and outlook of recent clinical data were refined. Analyst Commentary Recent Street research reflects a more cautious tone, with bearish analysts trimming price targets and rechecking their assumptions on risk and potential upside.Aggiornamento della narrazione • Dec 26
ALTO: Upcoming Late-Stage Data Will Shape Risk Profile Amid Measured Outlook
Analysts have modestly lowered their price target on Alto Ingredients, trimming fair value by $1 to $14 as they factor in slightly softer long term assumptions, while remaining encouraged by upcoming late stage data presentations. Analyst Commentary Bearish analysts have pointed to the recent price target reduction to $14 as evidence that expectations for Alto Ingredients' long term growth and profitability are being tempered, even as upcoming late stage data remains a potential catalyst.Articolo di analisi • Dec 22
Alto Ingredients, Inc.'s (NASDAQ:ALTO) Shares Leap 41% Yet They're Still Not Telling The Full Story
Alto Ingredients, Inc. ( NASDAQ:ALTO ) shares have continued their recent momentum with a 41% gain in the last month...Aggiornamento della narrazione • Dec 12
ALTO: Lower Discount Rate Will Support Improved Risk Profile Ahead
Analysts have raised their price target on Alto Ingredients by about $0.50, citing a lower perceived risk profile driven by a reduced discount rate, stronger expected revenue growth, and a modest improvement in projected profit margins and future valuation multiples. Analyst Commentary Bearish analysts remain cautious on Alto Ingredients despite the recent upward revision to the price target, emphasizing that the new target still embeds a meaningful discount to peers on key growth and profitability metrics.Articolo di analisi • Nov 07
Alto Ingredients, Inc. (NASDAQ:ALTO) Shares Fly 28% But Investors Aren't Buying For Growth
Alto Ingredients, Inc. ( NASDAQ:ALTO ) shares have continued their recent momentum with a 28% gain in the last month...Articolo di analisi • Jul 04
Alto Ingredients, Inc. (NASDAQ:ALTO) Held Back By Insufficient Growth Even After Shares Climb 31%
Alto Ingredients, Inc. ( NASDAQ:ALTO ) shares have continued their recent momentum with a 31% gain in the last month...
Nuova narrazione • May 04
CO2 Plant Integration Will Boost Production And Exports
Acquisition and integration of the CO2 processing plant are expected to improve financials through cost synergies, increased capacity, and enhanced revenue streams.Articolo di analisi • Apr 22
Health Check: How Prudently Does Alto Ingredients (NASDAQ:ALTO) Use Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Articolo di analisi • Nov 12
Alto Ingredients (NASDAQ:ALTO) Is Making Moderate Use Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Articolo di analisi • Jul 17
Alto Ingredients, Inc.'s (NASDAQ:ALTO) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Alto Ingredients, Inc. ( NASDAQ:ALTO ) shareholders are no doubt pleased to see that the share price has bounced 26% in...Articolo di analisi • Jun 28
Would Alto Ingredients (NASDAQ:ALTO) Be Better Off With Less Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Articolo di analisi • Jan 15
Here's Why Alto Ingredients (NASDAQ:ALTO) Can Afford Some Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Articolo di analisi • Dec 20
Alto Ingredients, Inc. (NASDAQ:ALTO) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Those holding Alto Ingredients, Inc. ( NASDAQ:ALTO ) shares would be relieved that the share price has rebounded 25% in...Articolo di analisi • Sep 15
Is Alto Ingredients (NASDAQ:ALTO) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Articolo di analisi • Apr 10
We Think Alto Ingredients (NASDAQ:ALTO) Has A Fair Chunk Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Articolo di analisi • Dec 16
Is Alto Ingredients (NASDAQ:ALTO) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Oct 19
Alto Ingredients: The Decline Has Created A Buying Opportunity
Summary Alto Ingredients has experienced some downward pressure over the past few months, even in spite of growing revenue and profits. Some of the bottom-line figures are deceptive given the role that a grant played in the matter, but the overall picture is still improving. Risk appears fairly low and shares look attractively priced right now. Just because an investment didn't offer attractive prospects at one point in time doesn't mean that the picture can't change for the better. As strong performance continues to be demonstrated and as shares of a company decline in price, the attractiveness of the firm in question can become more appealing, eventually reaching the point that assigning it a ‘buy’ rating just makes sense. One example of this can be seen by looking at Alto Ingredients (ALTO), a firm that produces and markets specialty alcohols and other essential ingredients for its customers. Recently, shares of the company have fallen even as fundamental performance remains strong. In addition to shares getting cheaper, the company continues to have cash in excess of debt totaling $22.2 million, leaving it with a good amount of wiggle room should market conditions worsen. Long term, investors should still expect significant volatility from a fundamental perspective. But given where shares are priced today, I do feel comfortable increasing my rating on the firm from a ‘hold’ to a ‘buy’, reflecting my opinion that the company’s stock should outperform the broader market for the foreseeable future. Robust strength changed my opinion Back in July of this year, I wrote an article that looked upon Alto Ingredients in a very neutral way. In truth, I was turned off by the volatility the company had seen in prior years, especially when it came to profitability. Having said that, profits in 2020 and 2021 proved to be rather robust for the company thanks to the change in market conditions. These changes, combined with a refusal by the market to push shares higher, leads into the stock looking rather cheap. But I still couldn't get over the company's business model and volatility as risk factors, ultimately resulting in a ‘hold’ rating for the business. Since then, shares of the firm have performed slightly better than I would have anticipated. While the S&P 500 has dropped by 12.9%, Alto Ingredients has seen a drop of 9.8%. Author - SEC EDGAR Data This return disparity is not necessarily large enough to be anything more than statistical noise. Having said that, it is also true that the company has continued to generate strong fundamental growth during this window of time. To see what I mean, we need only look at results covering the second quarter of the company's 2022 fiscal year. This is the only quarter for which data is now available that was not available when I last wrote about it. During that quarter, revenue came in at $362.2 million. That's 21.5% higher than the $298.1 million generated the same quarter only one year earlier. Total gallons of specialty alcohols the company sold actually dropped, declining from 125 million to 107.1 million. However, the firm did benefit from an increase in average pricing per gallon from $2.41 to $2.84. This drop in gallons sold was largely driven by a reduction in 3rd party gallons as the company continued to focus on the marketing and sales efforts associated with its own core production assets. The company also saw a more than doubling of sales of alcohol from its other production segment, driven by a rise in gallons sold of 14.4 million. This represents a 176% rise year over year. That unit also benefited from a $0.27 per gallon increase year over year. Meanwhile, essential ingredients revenue jumped by 221% to $23.4 million, driven by a 140% rise in volume and a 34% increase in average sales price per ton. Author - SEC EDGAR Data Clearly, the company's growth initiatives, particularly with regard to its emphasis on its own core production and to expanding into the specialty alcohols and essential ingredients spaces have proven to be beneficial for shareholders. The end result has also been an improvement in profitability. Net income in the second quarter of this year totaled $22.1 million. That's significantly higher than the $8.4 million reported one year earlier. Operating cash flow rose from $8.5 million to $9.6 million. But if we adjust for changes in working capital, the picture would have been even better, with the metric growing from $24.2 million to $38.4 million. Meanwhile, EBITDA also improved, rising from $17 million to $29.9 million. It is worth mentioning that profitability for the company was somewhat skewed. Although revenue has been rising, the firm benefited to the tune of $22.7 million from a grant associated with the USDA. Without that, operating income would have actually declined from $6.1 million in the second quarter of 2021 to negative $0.15 million the same time this year. It is worth mentioning that total results for the first half of the year did also come in stronger than what the company achieved in the first half of 2021. This much can be seen in the chart above. Author - SEC EDGAR Data Unfortunately, we don't really know what to expect for the rest of the current fiscal year. Given the one-time nature of the grant I mentioned, it's difficult to know what the organic potential the firm is. So instead of projecting out what results might look like for the rest of the year, I decided to price the company using data from 2021. Using this approach, the firm is trading at a price to adjusted operating cash flow multiple of 6.9 and at an EV to EBITDA multiple of 3.4. As part of my analysis, I compared the company to two other firms that are somewhat similar in nature. On a price to operating cash flow basis, these companies traded at multiples of 1.5 and 15.3. And using the EV to EBITDA approach, the multiples were 0.6 and 6.3. In both cases, our prospect was in the middle of the two.Seeking Alpha • Sep 12
Alto Ingredients gains on announcing $50M share repurchase program
Alto Ingredients (NASDAQ:ALTO) climbs on 4.76% premarket on authorizing share repurchase program for up to $ 50M of its common stock with an initial purchase authorization of $10M. “Given our positive long-term outlook, we believe our shares are currently undervalued. Based on the strength of our balance sheet, an opportunity exists to create value for our stockholders by repurchasing stock while we continue to upgrade our equipment and operating systems to increase efficiency and plant reliability, expand our corn storage capacity, enhance our specialty alcohol production, broaden our distribution, and reinvest in essential ingredients capabilities,” said Michael Kandris, CEO of Alto Ingredients.Articolo di analisi • Aug 31
Alto Ingredients (NASDAQ:ALTO) Seems To Use Debt Quite Sensibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Rendimenti per gli azionisti
| ALTO | US Chemicals | US Mercato | |
|---|---|---|---|
| 7D | 2.4% | 0.9% | -2.4% |
| 1Y | 413.6% | 4.9% | 21.5% |
Ritorno vs Industria: ALTO ha superato il US Chemicals che ha restituito 4.9 % nell'ultimo anno.
Rendimento vs Mercato: ALTO ha superato il mercato US che ha restituito 21.5 % nell'ultimo anno.
Volatilità dei prezzi
| ALTO volatility | |
|---|---|
| ALTO Average Weekly Movement | 10.9% |
| Chemicals Industry Average Movement | 7.1% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Prezzo delle azioni stabile: ALTO non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 11% ) di ALTO è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 2003 | 390 | Bryon McGregor | www.altoingredients.com |
Alto Ingredients, Inc. produce, distribuisce e commercializza alcoli speciali, carburanti rinnovabili e ingredienti essenziali negli Stati Uniti. L'azienda opera in tre segmenti: Marketing e distribuzione, Produzione del campus di Pekin e Produzione occidentale. L'azienda offre alcoli speciali utilizzati per collutori, cosmetici, prodotti farmaceutici, igienizzanti per le mani, disinfettanti e detergenti per i mercati della salute, della casa e della bellezza; spiriti neutri di cereali utilizzati per le bevande alcoliche e l'aceto, nonché germe di mais utilizzato per gli oli di mais nei mercati degli alimenti e delle bevande; alcoli e altri prodotti per applicazioni di verniciatura e fertilizzanti nei mercati dell'industria e dell'agricoltura; e ingredienti essenziali, tra cui lievito secco, farina proteica di mais, mangimi proteici di mais, germe di mais, grani di distillatori e mangimi liquidi per applicazioni di mangimi commerciali per animali e alimenti per animali domestici, nonché lievito e gas CO2 liquido per il consumo umano.
Alto Ingredients, Inc. Riepilogo dei fondamenti
| ALTO statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$438.57m |
| Utili (TTM) | US$28.02m |
| Ricavi(TTM) | US$916.07m |
15.6x
Rapporto P/E0.5x
Rapporto P/SALTO è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| ALTO Conto economico (TTM) | |
|---|---|
| Ricavi | US$916.07m |
| Costo del fatturato | US$870.13m |
| Profitto lordo | US$45.94m |
| Altre spese | US$17.92m |
| Utili | US$28.02m |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | 0.36 |
| Margine lordo | 5.01% |
| Margine di profitto netto | 3.06% |
| Rapporto debito/patrimonio netto | 29.2% |
Come si è comportato ALTO nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/06/11 18:00 |
| Prezzo dell'azione a fine giornata | 2026/06/11 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Alto Ingredients, Inc. è coperta da 9 analisti. 2 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Carter Driscoll | B. Riley Securities, Inc. |
| Hamed Khorsand | BWS Financial Inc. |
| Eric Stine | Craig-Hallum Capital Group LLC |